Immune system identifies "double insurance" for new coronary mutant virus

The strain has been the subject of widespread concern from scientists since its inception, as many in-body experiments have shown that it can evade the identification of certain meso-antibodies, thereby reducing the protection of the body's immune response.
and Johnson and Johnson's vaccine trials have validated the results of in-body trials from the perspective of human clinical trials.
, what are our responses to these new coronary mutant strains? What are the findings of these trials on the design of the new crown vaccine? Last week, several companies said they were working on a new generation of new crown vaccines for mutant strains.
johnson and Johnson executives stressed the importance of vaccines stimulating the body's T-cell immune response in a conference call to release clinical results for Phase 3.
the company's vaccine is 85 percent effective in protecting severe COVID-19, and its ability to protect against severe illnesses is not affected by the B.1.351 mutation.
Johnson and Johnson executives point out that the vaccine-inspired strong T-cell immune response may be one of the important reasons why the vaccine's ability to protect against severe COVID-19 is not affected.
T-cell immune response is an important part of the body's immune response.
activation of CD4-positive T cells can help B cells to produce nalocular antibodies and activate CD8-positive T-cells.
CD8-positive T cells can destroy infected cells.
study published in Cell Report Medicine, a sub-issue of Cell, on Tuesday.
The new coronavirus antigen protosetotes identified by human T-cells are very different from those produced by B cells and are more diverse and not limited to the subject binding domain (RBD) of the hedgehog protein or hedgehog protein.
T cells are still well-identified, even for new strains of the new coronary mutant virus.
that this provides a good basis for the prevention of severe COVID-19 and may further guide future vaccine design.
the study, scientists obtained blood samples from 99 COVID-19 rehabilitation patients and accurately tested viral antigen esopterials identified by CD4-positive and CD8-positive T-cells for the new coronavirus.
they found that CD4-positive and CD8-positive T-cells identified new coronavirus antigens are mainly distributed on 8 to 9 viral proteins, in addition to the well-known pyrethroid protein (S protein), but also identify membrane protein (M), nuclear shell protein (N), and ORF3a, nsp12 and other non-structural proteins.
specific to the prickly proteins used in most vaccine developments, cd4-positive T-cells also recognize antigen protosetotics that are significantly different from between meso-antibodies.
Interestingly, most of the prickly protein protosets identified by CD4-positive T cells are not in the subject binding domain (RBD), but in the N-side domain (NTD), C-side domain (CT) and fusion protein (FP) domains of the hedgehog protein.
The results mean that the body's T-cell immune response to the new coronavirus is very diverse and can target multiple different cousins of the new coronavirus, making it more difficult for the new coronavirus to evade T-cell identification through genetic mutations.
also tested the effects of the new crown mutant strain of B.1.1.7 in the UK on T-cell recognition.
they found that the antigen cousins affected by the B.1.1.7 mutation accounted for only 8% of the total number of CD4-positive T-cell identification tables, and that 92% of the antigens were still identifiable by T-cells.
Alessandro Sette of the La Jolla Institute for Immunology, one of the study's senior authors, said computational models showed that the B.1.135 mutant strain could also be identified by 90 percent of T-cells.
may not be enough to prevent infection, it may make the disease much lighter.
," Added Professor Sette.
In addition, the researchers note in the discussion of the article that since the activation of CD4-positive T cells plays an important role in assisting B cells in producing antibodies and activating CD8-positive T-cells, the ability to activate this T-cell type should be considered in vaccine design.
the RBD itself lacks an antigen prototyping position that activates CD4-positive T cells, other parts of the vaccine should be considered to support the activation of sufficient CD4-positive T-cells.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
resources: . Retrieved January 28, 2021, from [2] Tarke et al., (2021). Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Reports Medicine, [3] Why we shouldn't panic about those coronavirus variants just yet. Retrieved January 31, 2021, from